Accession Number: | 0001209191-20-008870 |
Date: | 2020-02-10 |
Issuer: | VERTEX PHARMACEUTICALS INC / MA (VRTX) |
Original Submission Date: |
LEE YUCHUN
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON, MA 02210
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-02-10 | M | 1,181 | a | $57.27 | 3,056 | direct | ||
COMMON STOCK | 2020-02-10 | S | 120 | d | $240.04 | 2,936 | direct | ||
COMMON STOCK | 2020-02-10 | S | 360 | d | $241.61 | 2,576 | direct | ||
COMMON STOCK | 2020-02-10 | S | 360 | d | $242.86 | 2,216 | direct | ||
COMMON STOCK | 2020-02-10 | S | 229 | d | $243.55 | 1,987 | direct | ||
COMMON STOCK | 2020-02-10 | S | 112 | d | $244.79 | 1,875 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTIONS (RIGHT TO BUY) | 57.27 | 2020-02-10 | deemed execution date | M | 1,181 (d) | 2022-09-13 | common stock 1,181 | $57.27 | 13,125 | direct |
ID | footnote |
---|---|
f1 | transaction made pursuant to mr. lee's company approved trading plan under rule 10b5-1. |
f2 | open market sales reported on this line occurred at a weighted average price of $240.04 (range $239.59 to $240.49). |
f3 | mr. lee undertakes to provide (upon request by the sec staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
f4 | open market sales reported on this line occurred at a weighted average price of $241.61 (range $241.26 to $241.87). |
f5 | open market sales reported on this line occurred at a weighted average price of $242.86 (range $242.37 to $243.36). |
f6 | open market sales reported on this line occurred at a weighted average price of $243.55 (range $243.46 to $243.72). |
f7 | open market sales reported on this line occurred at a weighted average price of $244.79 (range $244.78 to $244.84). |
f8 | fully vested. |